Tratamiento combinado de la hipertensión arterial pulmonar

Román Broto, Antonio; Monforte Torres, Victor.
Arch. bronconeumol. (Ed. impr.) ; 45(1): 36-40, ene. 2009.
Artículo en Español | IBECS (España) | ID: ibc-59864

Documentos relacionados

  1. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
  2. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension.
  3. Phosphodiesterase 5: A Novel Therapeutic Target in Long QT Syndrome.
  4. Phosphodiesterase 5a Signalling in Skeletal Muscle Pathophysiology.
  5. Re: PDE5A Polymorphisms Influence on Sildenafil Treatment Success.
  6. A synthetic mimic of phosphodiesterase type 5 based on corona phase molecular recognition of single-walled carbon nanotubes.
  7. Phosphodiesterase 5A regulates the vomeronasal pump in mice.
  8. Improving Erectile Dysfunction Management Among Asian Men With Diabetes Using the Knowledge Translation Intervention.
  9. Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety.
  10. Aphrodisiac Performance of Bioactive Compounds from <i>Mimosa pudica</i> Linn.: In Silico Molecular Docking and Dynamics Simulation Approach.